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ABSTRACT
ObjectiveTodescribetheoutcomesofclinicalevaluation,
skin testing, and vaccine challenge in adolescent
schoolgirls with suspected hypersensitivity to the
quadrivalenthumanpapillomavirusvaccineintroducedin
Australian schools in 2007.
Design Retrospective cohort study.
Setting Two tertiary paediatric allergy centres in Victoria
and South Australia, Australia.
Participants 35 schoolgirls aged 12 to 18.9 years with
suspected hypersensitivity reactions to the quadrivalent
human papillomavirus vaccine.
Main outcome measures Clinical review and skin prick
andintradermaltestingwiththequadrivalentvaccineand
subsequent challenge with the vaccine.
Results 35 schoolgirls with suspected hypersensitivity to
the quadrivalent human papillomavirus vaccine were
notifiedtothespecialisedimmunisationservicesin2007,
after more than 380000 doses had been administered in
schools. Of these 35 schoolgirls, 25 agreed to further
evaluation. Twenty three (92%) experienced reactions
afterthefirstdose.Thirteen(52%)experiencedurticariaor
angio-oedema, and of these, two experienced
anaphylaxis. Thirteen had generalised rash, one with
angio-oedema. The median time to reaction was
90 minutes. Nineteen (76%) underwent skin testing with
the quadrivalent vaccine: all were skin prick test negative
and one was intradermal test positive. Eighteen (72%)
were subsequently challenged with the quadrivalent
vaccine and three (12%) elected to receive the bivalent
vaccine. Seventeen tolerated the challenge and one
reported limited urticaria four hours after the vaccine had
been administered. Only three of the 25 schoolgirls were
found to have probable hypersensitivity to the
quadrivalent vaccine.
Conclusion True hypersensitivity to the quadrivalent
human papillomavirus vaccine in Australian schoolgirls
was uncommon and most tolerated subsequent doses.
INTRODUCTION
A quadrivalent human papillomavirus vaccine (Gar-
dasil; Merck, NJ, USA) was included in the Australian
national immunisation programme in April 2007 for
females aged 12-26 years. Adolescent schoolgirls
receivedthevaccineinasecondaryschoolvaccination
programme and reports of vaccine related adverse
eventssoonfollowed.
1Constituentsofthequadrivalent
vaccine, such as aluminium salts,
23 polysorbate 80,
4
and yeast,
5 have been associated with hypersensitivity
reactions. The vaccine also shares constituents with
othervaccines,suchashepatitisB(H-B-VaxII;Merck,
NJ, USA) and diphtheria, tetanus, and pertussis
(Boostrix; GlaxoSmithKline, Rixensart, Belgium),
whicharegiventoAustralianadolescentsatage13and
15 years, respectively. A bivalent human papilloma-
virus vaccine (Cervarix; GlaxoSmithKline, Rixensart,
Belgium) lacks these constituents and may be an
alternative for patients with hypersensitivity to the
quadrivalent vaccine (table 1).
Wedescribetheoutcomesofclinicalevaluation,skin
testing,andvaccinechallengeinAustralianadolescent
schoolgirls with suspected hypersensitivity to the
quadrivalent human papillomavirus vaccine.
METHODS
In the Australian states of Victoria and South Australia,
specialised immunisation services are notified of
reported vaccine related adverse events. Adolescent
schoolgirls with suspected hypersensitivity reactions to
thequadrivalenthumanpapillomavirusvaccine,includ-
ing urticaria, generalised rash, angio-oedema, or ana-
phylaxis, were referred to tertiary paediatric allergy
centres for further evaluation and are included in this
retrospective cohort study. We include only girls who
received the vaccine in school and not those who may
have received the vaccine elsewhere. A detailed history
ofthereactionwasobtained,includingpreviousdosesof
the quadrivalent vaccine, concomitant vaccines, and
time and severity of reaction. We also recorded any
history of atopic disease, recurrent urticaria, or drug or
vaccine related adverse reactions.
Skin prick and intradermal tests were carried out with
1:10 dilutions of both the quadrivalent and the bivalent
human papillomavirus vaccines and 100 mg/ml
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many).
6Weusedhistamineandnormalsalineaspositive
andnegativecontrols.Additionalskinprickteststoother
potential allergens were done as guided by clinical
history. We measured skin wheals 15 and 20 minutes
afterskinprickandintradermaltesting,respectively,and
considered diameters of 3 mm or more above the saline
control as a positive result.
Vaccine challenges were administered intra-
muscularly under medical supervision. All the girls
were offered challenge with the quadrivalent vaccine
unlesstherewaspreviousanaphylaxisorapositiveskin
test result to the vaccine. A 0.1 ml dose was followed
30minuteslaterbya0.4mldose.Thebivalentvaccine
(0.5 ml) was given if requested by the recipient. We
followed up the schoolgirls by telephone one week
after vaccination and recorded any adverse events.
Further vaccinations were planned for those who
tolerated the challenge, to complete the three dose
schedule.
RESULTS
Thirty five schoolgirls with suspected hypersensitivity
tothequadrivalentvaccinewerereportedin2007,after
more than 380000 vaccine doses had been adminis-
tered in schools in Victoria and South Australia.
Twenty five of these schoolgirls (71%) agreed to
undergo further evaluation and were reviewed
between August 2007 and February 2008, at a median
of 5.7 months(range 1.6-9.9 months) afterthe reaction
(figure). The age of the schoolgirls, proportion with
reactionstothefirstdose,andproportionwithurticaria
reactions were similar in those excluded and those
evaluated. No cases of angio-oedema or anaphylaxis
occurred in the excluded group (six in the evaluated
group) and time to reaction was significantly longer
(median 24 hours) and positively skewed than in the
evaluated group.
The median time to reaction after vaccination in the
evaluated group was 90 minutes. Thirteen of the 25
evaluated schoolgirls experienced urticaria or angio-
oedema, and of these, two experienced anaphylaxis
(table 2). Thirteen experienced generalised rash, one
with angio-oedema.
Nineteen (76%) of the 25 evaluated schoolgirls
received only the quadrivalent vaccine, whereas six
hadconcomitantvaccines(table 2).Twentythreeofthe
25 (92%) reported reactions after the first dose of
Risk assessment (n=25)
Suspected hypersensitivity reactions (n=35)
Skin prick test (n=19)
Intradermal test (n=19)
Vaccine challenge (n=21)
Excluded (n=10):
    Completed third dose of quadrivalent vaccine (n=2)
   Declined further evaluation or human papillomavirus 
 vaccine  (n=3)
  Advised against further human papillomavirus vaccines 
  by other doctors (n=2)
  No contact details (n=3)
6 of 10 reported urticaria (no anaphylaxis)
Skin tests not done (n=6):
 Declined  (n=2)
  Deemed unnecessary by clinician (n=4)
Excluded (n=4):
  Anaphylaxis with positive intradermal test result (n=1)
  Received third dose of quadrivalent vaccine (n=2)
  Declined vaccine challenge (n=1)
Flow chart of clinical evaluation through trial
Table 1 |Examples of constituents of vaccines
Variables
Vaccine (manufacturer)
H-B-Vax II (Merck) Boostrix (GlaxoSmithKline) Gardasil (Merck) Cervarix (GlaxoSmithKline)
Microorganism Double stranded DNA hepatitis virus
family Hepadnaviridae
Bordetella pertussis,
Corynebacterium diphtheriae,
Clostridium tetani
Recombinant human papillomavirus
proteins,virus-like particles6,11,16,
and 18
Recombinant human papillomavirus
proteins, virus-like particles 16 and 18
Medium Saccharomyces cerevisiae Stainer-Scholte liquid; Fenton
medium; Lantham medium
Saccharomyces cerevisiae Baculovirus or Trichoplusnia
Preservative None Polysorbate 80 ≤100 μg;
formaldehyde
Polysorbate 80 50 μg; L-histidine None
Adjuvant Aluminium hydroxyphosphate
sulphate; potassium salt
Aluminium hydroxide; sodium
chloride
Aluminium hydroxyphosphate
sulphate; sodium chloride; sodium
borate
Aluminium hydroxide and
monophosphoryl lipid A; sodium
chloride; sodium phosphate
monobasic
Current immunisation
schedule in Australia
Infant schedule; catch-up schedule
11-15 years
15-17 years School years 7, 10, 11, and 12 until
26years(registeredfor9-26yearolds)
(registered for 10-45 years)
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after the second dose, and of these, three reported
reactions after the first and the second doses. One
patient reported a reaction after the third dose.
Fifteen (60%) of the 25 evaluated schoolgirls had a
history of current atopic disease: allergic rhinitis in 12
(48%), asthma in eight (32%), atopic dermatitis in five
(20%), allergic conjunctivitis in five (20%), and food
allergyinthree(12%).Twogirlshadrecurrenturticaria
and none had a history of hypersensitivity to yeast,
drugs,orvaccines.Food,environmentalallergens,and
drug allergens that may have been associated with the
Table 2 |Details of 25 girls reporting adverse reactions to the quadrivalent human papillomavirus vaccine
Vaccine category, dose,
andconcomitantvaccines
Suspected
hypersensitivityreaction
Onset of
reaction (min)
Skin prick test
result
Intradermal
test result Vaccine challenge
Challenge
reaction Notes
Probable hypersensitivity
(median 17.5 minutes):
Third dose Urticaria, angio-oedema,
laryngeal oedema,
tachypnoea, palpitations
390 Negative Negative NA NA Anaphylaxis after third
dose
First (and second) dose Urticaria (urticaria, angio-
oedema, hoarse voice,
laryngeal oedema)
20 (15) Negative Positive NA NA Anaphylaxis after second
dose
First dose Urticaria 15 Negative Negative Quadrivalent HPV vaccine Reported limited
urticaria four
hours later
Possible hypersensitivity
(median 16 hours):
Second dose Urticaria 960 Negative Negative Elected not to proceed
with challenge before
evaluation
Elected not to
proceed with
challengebefore
evaluation
Hyperventilating after
intradermal test. Reported
non-specific limited rash
several hours after
intradermal test
Unlikely hypersensitivity
(median 19 hours):
First dose plusH-B-Vax II Generalised rash, angio-
oedema
2 Negative Negative Bivalent HPV vaccine None Hypersensitivity unlikely as
did not receive
quadrivalent vaccine
First dose plusH-B-Vax II Generalised rash 120 Negative Negative Bivalent HPV vaccine None Hypersensitivityunlikely as
did not receive
quadrivalent vaccine
First dose Generalised rash 2160 Negative Negative Quadrivalent HPV vaccine Reported
nausea,
vomiting, and
lethargy two
days later
Hypersensitivityunlikely as
reaction was different to
previous reaction
First dose plusH-B-Vax II Urticaria, angio-oedema 2880 Negative Negative Bivalent HPV vaccine None Hypersensitivityunlikely as
did not receive
quadrivalent vaccine
Not hypersensitivity
(median 90 minutes):
First dose plus Varilrix
plus tetanus
Generalised rash 1440 Negative Negative Quadrivalent HPV vaccine None
First dose plusH-B-Vax II Generalised rash
(eczema)
1440 NA NA Quadrivalent HPV vaccine None Skin testing deemed
unnecessary
First dose Generalised rash 1080 NA NA Quadrivalent HPV vaccine None Skin testing deemed
unnecessary
First dose Generalised rash 1080 NA NA Quadrivalent HPV vaccine None Declined skin testing
First dose Generalised rash 180 Negative Negative Quadrivalent HPV vaccine None
First dose plus Boostrix Generalised rash 720 Negative Negative Quadrivalent HPV vaccine None
First dose Urticaria 2880 Negative Negative Quadrivalent HPV vaccine None
First dose Angio-oedema 5 Negative Negative Quadrivalent HPV vaccine None
First dose Generalised rash 90 Negative Negative Quadrivalent HPV vaccine None
First dose Generalised rash 1440 NA NA Quadrivalent HPV vaccine None Declined skin testing
First dose Angio-oedema 1440 Negative Negative Quadrivalent HPV vaccine None
First dose Urticaria 15 Negative Negative Quadrivalent HPV vaccine None
First (and second) dose Urticaria (urticaria) 30 (20) Negative Negative Quadrivalent HPV vaccine None Twin of schoolgirl
Third dose Urticaria 10 Negative Negative NA NA Twin of schoolgirl
First dose Generalised rash,
tachypnoea
20 Negative Negative Quadrivalent HPV vaccine None Thought to hyperventilate
after first dose
First dose Generalised rash 30 Negative Negative Quadrivalent HPV vaccine None
First (and second) dose Urticaria (urticaria) 10 (10) Negative Negative Quadrivalent HPV vaccine None
HPV=human papillomavirus; NA=not applicable; H-B-Vax II=vaccine against hepatitis B (Merck); Varilix=vaccine against varicella (GlaxoSmithKline); Boostrix=vaccine against diphtheria,
tetanus, and pertussis (GlaxoSmithKline).
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detailed history taking and, if clinically indicated, skin
prick tests.
Nineteen of the 25 evaluated schoolgirls (76%)
underwent skin prick testing to the quadrivalent
vaccine, polysorbate 80, and bivalent vaccine. All the
results were negative. The 19 schoolgirls underwent
intradermal testing, of which one (table 2) had a
positiveresulttothequadrivalentvaccineandnegative
resultstopolysorbate80andthebivalentvaccine.One
schoolgirl experienced hyperventilation during intra-
dermal testing (table 2) and reported a limited non-
specific rash several hours later. She declined further
vaccination against human papillomavirus.
Challengewiththequadrivalentvaccinewascarried
outin18(72%)ofthe25evaluatedschoolgirls.Threeof
thesevenschoolgirlswhowerenotchallengedwiththe
quadrivalent vaccine elected to receive the bivalent
vaccine as they had concerns about the quadrivalent
vaccine despite a negative skin test result. Vaccine
challenges were not done in the two schoolgirls who
had completed the three doses of the schedule or the
one girl who declined further vaccination, and
challenge was contraindicated in one girl who had
anaphylaxis and a positive skin test result to the
quadrivalent vaccine.
Seventeen of the 18 schoolgirls challenged with the
quadrivalent vaccine and all three challenged with the
bivalent vaccine remained well one week after
vaccination. One schoolgirl reported limited urticaria
overthelimbsandtrunkfourhoursafterchallengewith
the quadrivalent vaccine (table 2). Supervised
challenge with the bivalent vaccine for her third dose
of human papillomavirus vaccine was well tolerated.
The25evaluatedschoolgirlswereclassifiedintoone
of four categories (table 2): probable hypersensitivity
—those with anaphylaxis, a positive skin test result for
the quadrivalent vaccine, or reproducible reactions to
challenge with the quadrivalent vaccine; possible
hypersensitivity—those with reactions to skin testing
who were not challenged with the quadrivalent
vaccine; unlikely hypersensitivity—those with nega-
tive skin test results to the quadrivalent vaccine who
were not challenged with the quadrivalent vaccine, or
were challenged with the quadrivalent vaccine but did
not experience a reproducible reaction; and not
hypersensitivity—those with negative skin test results
forthequadrivalentvaccineandnoadversereactionto
subsequent challenge with the quadrivalent vaccine.
Schoolgirls in the probable hypersensitivity group
weremorelikelytopresentwithurticariathanthosein
the unlikely hypersensitivity group (likelihood ratio
9.0) and not hypersensitivity group (10.2), and had a
mediantimetoreactionof17.5minutescomparedwith
19 hours in the unlikely hypersensitivity group and
90 minutes in the not hypersensitivity group (table 2).
Other clinical features, including number of doses of
thequadrivalentvaccine,concomitantvaccines,recur-
rence of reactions to the quadrivalent vaccine, and
current atopic disease or recurrent urticaria, did not
predict hypersensitivity to the quadrivalent vaccine.
DISCUSSION
Weevaluatedsuspectedhypersensitivityinadolescent
females immunised with a human papillomavirus
vaccine in Australian schools. Only three of the 25
evaluated schoolgirls had probable hypersensitivity to
the quadrivalent human papillomavirus vaccine after
380000 doses had been administered in schools.
Seventeen of the 18 girls subsequently challenged
with the quadrivalent vaccine tolerated revaccination.
Our data suggest that true hypersensitivity to the
quadrivalent vaccine is uncommon and that suspected
hypersensitivity reactions such as urticaria are often
idiosyncratic and not usually a contraindication to
further vaccinations. Studies of other vaccines have
found that most reactions after immunisation are not
due to hypersensitivity and revaccination is usually
well tolerated.
7-9
Although we excluded 10 of 35 schoolgirls with
suspected hypersensitivity to the quadrivalent vaccine
from our evaluation, reactions in the excluded group
were mostly mild and delayed in presentation,
suggesting that we did not miss any important cases
of suspected hypersensitivity to the quadrivalent
vaccine. All reported cases of anaphylaxis were
evaluated.
Time to anaphylaxis was 15 minutes in one girl and
6.5 hours in another. As anaphylaxis after childhood
vaccinations usually occurs within one hour,
1011 6.5
hours is beyond any standard observation period after
immunisation. Consistent with the delayed presenta-
tion, one of the girls had no evidence of IgE mediated
hypersensitivity to the quadrivalent vaccine and we
postulate her reaction was mediated by IgG or
complement, or both. As she was not rechallenged
with the quadrivalent vaccine, however, hypersensi-
tivity was not confirmed.
Oneofthegirlshada positiveintradermaltestresult
tothequadrivalentvaccinethatwasconsistentwithIgE
mediated hypersensitivity. We were unable to deter-
minewhetherherreactionwasduetotherecombinant
viral-like particles or other constituents of the vaccine
suchasaluminiumhydroxyphosphatesulphate.Asshe
hadnohistoryofreactionstoyeast,andskintestingfor
polysorbate 80 gave a negative result, IgE mediated
hypersensitivitytothesecomponentswasunlikely.For
females with probable hypersensitivity to the quad-
rivalent vaccine, immunoblot analysis and measure-
ment of specific IgG and IgE to the individual vaccine
components would provide further information.
Our study describes two cases of anaphylaxis after
380000 doses of the quadrivalent vaccine had been
WHAT IS ALREADY KNOWN ON THIS TOPIC
Hypersensitivity reactions to vaccines are uncommon
WHAT THIS STUDY ADDS
True hypersensitivity to the quadrivalent human
papillomavirus vaccine is uncommon and most females
tolerate subsequent doses
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system for reporting vaccine related adverse events in
Australia, the quadrivalent human papillomavirus
vaccine is a new vaccine and there is a high level of
awareness of the importance of reporting adverse
events in the school immunisation programme. One
study estimated that if 80% of eligible US adolescent
females were to receive a saline injection according to
the vaccination schedule for human papillomavirus, 3
per100000adolescentswouldrequireemergencycare
for asthma or allergy within 24 hours of vaccination.
12
As allergic symptoms are common, studies of adverse
events to the quadrivalent vaccine should take these
“baseline” rates into consideration. An Australian
human papillomavirus vaccination programme regis-
ter (www.hpvregister.org.au/), established in August
2008, will facilitate more accurate determination of
rates of hypersensitivity reactions not possible from
current data sources.
In conclusion, suspected hypersensitivity reactions
to the human papillomavirus quadrivalent vaccine
require further evaluation to exclude IgE mediated
reactions. Most females with suspected hypersensitiv-
ity to this vaccine tolerate revaccination. Our clinical
recommendationisthatfemales withsuspectedhyper-
sensitivity to the quadrivalent vaccine should be
evaluated before receiving more doses, and any
challenges with the same vaccine should be carried
outinasupervisedsetting.Furtherstudiesarerequired
to investigate the mechanisms of hypersensitivity to
this vaccine.
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